Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cangen Biotechnologies and Olympus Expand Collaboration to Develop High-Throughput Molecular Diagnostic Test for Early Detection of Lung Cancer.


BETHESDA, Md. -- Cangen Biotechnologies, Inc. today announced the expansion of its ongoing research collaboration with Olympus Corporation This article refers to a Japanese camera maker. For other meanings, see Olympus (disambiguation).

Olympus Corporation (オリンパス株式会社
, initiated in May 2005, to develop a hybrid DNA-based and protein-based diagnostic test for use in the early detection of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . The expanded collaboration includes funding for a prospective clinical study.

The goal of this research collaboration is the establishment of a blood-based molecular diagnostic test for early detection of lung cancer. The identification of specific DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 markers is underway. Several key DNA markers with 70-80% accuracy have been identified from surgically resected samples obtained by Cangen from Hyundai Hospital in Korea during 2005. The identified markers can be used as a hybrid with protein-based markers to improve sensitivity and specificity. Olympus and Cangen are aiming for FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 approval after approximately two years.

Cangen has commenced patient recruitment for the study at clinical sites in Asia and will receive funding from Olympus in support of the study and ongoing research and clinical development efforts regarding lung cancer detection. Cangen will manage the study from its Asia Clinical Trial Center in Seoul, Korea.

"With our partners at Olympus, we have made dramatic progress over the last six months in the development of the test and platform for the early detection of lung cancer," stated Chul So Moon, M.D., Ph.D., Chief Executive Officer and Chief Science Officer of Cangen Biotechnologies. "This additional commitment by Olympus to support the clinical development of our lung cancer detection technology underscores the viability of the technology as a key tool in saving human life."

"This expansion of the collaboration launched last May continues our joint efforts to commercialize Cangen's promising cancer diagnostic technologies," said Hiroyuki Yoshimori, Division Manager of Biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 Business Incubation incubation /in·cu·ba·tion/ (in?ku-ba´shun)
1. the provision of proper conditions for growth and development, as for bacterial or tissue cultures.

2.
 Division in Olympus Corporation. "We are most pleased to support the clinical study. Commercialization of this technology will be for be mutual benefit of both companies, " added Mr. Yoshimori.

Richard A. Silfen, President and Chief Financial Officer of Cangen Biotechnologies, added, "The opportunity to expand our collaboration with Olympus into the clinical development setting will accelerate our effort to commercialize the lung cancer diagnostic product. Equally important, by developing the ability to perform the test on Olympus' market-leading platform, we are seeking to make the diagnostic product available globally to people at risk of contracting the disease."

Cangen Biotechnologies, Inc. is a cancer-focused biotechnology company developing non-invasive diagnostic tests for early detection of cancer, chemosensitivity technologies to enhance the selection of cancer therapeutic regimes as well as targeted drug and biologic cancer therapies, including vaccines. The company is currently enrolling patients in a Phase 3 study to evaluate a molecular diagnostic test for the early detection of bladder cancer bladder cancer

Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor.
, based on microsatellite See miniaturized satellite.  DNA instability. Cangen Biotechnologies is headquartered in Bethesda, MD, has laboratories in Rockville, MD and conducts additional research at Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C.  in Baltimore, MD. The company has a clinical trial center in Seoul, Korea and operations in Tokyo, Japan. Cangen is on the world wide web at http://www.cangenbio.com.

Olympus Corporation is a global precision technology leader in designing and delivering solutions for medical and healthcare, imaging and information, and industrial applications. Olympus leverages research and development investment in technology and manufacturing processes across various business lines which include;

--Gastrointestinal endoscopes, accessories, and minimally invasive invasive /in·va·sive/ (-siv)
1. having the quality of invasiveness.

2. involving puncture of the skin or insertion of an instrument or foreign material into the body; said of diagnostic techniques.
 surgical products;

--Advanced clinical and research microscopes;

--Lab automation systems, chemistry-immuno and blood analyzers and reagents;

--Digital and film cameras and digital voice recorders A digital, handheld device that is used to record short reminders. Very lightweight and typically using AAA batteries, such devices use flash memory to hold up to 100 messages and more. Messages can be retrieved sequentially or by direct access by message number. See microcassette. .

--Information processing equipment, industrial video scopes, and industrial microscopes
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jan 6, 2006
Words:579
Previous Article:invivodata Announces Its Record Growth Continuing in 2005; New and Repeat Business Fuels 17th Consecutive Growth Quarter.
Next Article:Are Super Bowl Advertisers Calling the Right Plays in Search?; Reprise Media Announces Plans for Their Second Annual Super Bowl Search Marketing...
Topics:



Related Articles
GEN-PROBE ACQUIRES DIAGNOSTIC RIGHTS TO PROSTATE CANCER GENE.
ABBOTT/EUROPROTEOME TO DEVELOP BREAST CANCER DIAGNOSTIC TESTS.
Circulating cells in cancer detection.
SBIR/STTR: circulating cells and DNA in cancer detection.
Olympus, Cangen Biotechnologies to Expand Joint Development of Molecular Diagnostic Test for Early Lung Cancer Detection.
Lifeline Biotechnologies Completes Initial Patient Testing of the OvaScope(TM).
ORION/UNIVERSITY OF GLASGOW TO IDENTIFY EPIGENETIC BIOMARKERS.
Lifeline Biotechnologies, Inc. Initiates Latin American MastaScope(TM) Sales Effort.
Lifeline Biotechnologies Welcomes Dr. Kefah Mokbel to Its Medical Advisory Board.
Blood test to detect lung cancer.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles